instruction
stringclasses 1
value | input
stringlengths 17
568
| output
stringlengths 1
80
|
|---|---|---|
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | In addition, an immediate erythematous macule was observed on the photopatch test site of mequitazine directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy. | Erythema |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to promethazine, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine. | Drug hypersensitivity |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Mequitazine seemed to play a part similar to chlorpromazine, and absence of mequitazine-induced photosensitivity may be due to a relatively low dosage of the drug. | Photosensitivity reaction |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Two cases of mequitazine-induced photosensitivity reactions. | Photosensitivity reaction |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems. | Photosensitivity reaction |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Keratitis in methamphetamine abusers. | Keratitis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Methamphetamine's extensive physiologic effects, inconsistent street purity, and multiple routes of administration offer many possibilities for injury to the cornea. | Injury corneal |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Potential causes of methamphetamine-related keratitis can be divided into four categories resulting from (a) direct pharmacologic and physical effects of methamphetamine; (b) the toxic effects of diluting or "cutting" agents such as lidocaine and quinine; (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product. | Keratitis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The increasing prevalence of methamphetamine abuse and the severity of the associated ulcers should alert ophthalmologists to the problem of methamphetamine-related keratitis. | Keratitis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We report four cases of severe corneal ulceration in methamphetamine abusers. | Ulcerative keratitis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | BACKGROUND: Methotrexate (MTX) may induce liver damage, which in some psoriatics will lead to fibrosis or cirrhosis. | Hepatic cirrhosis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | CONCLUSIONS: This study confirmed that in most patients MTX-induced liver cirrhosis is not aggressive. | Hepatic cirrhosis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | However, continued low-dose MTX led, in spite of normal liver tests, 8 years after the last biopsy to liver failure and death in 1 of our patients. | Death |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Methotrexate-induced liver cirrhosis. | Hepatic cirrhosis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Studies performed 10 years ago on 25 patients with MTX-induced liver cirrhosis indicated that this type of cirrhosis was not of an aggressive nature. | Hepatic cirrhosis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | After therapy for diabetic coma with insulin (containing the preservative cresol) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and respiratory and metabolic acidosis and lost consciousness. | Pyrexia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | However, other factors or drugs (e.g. cresol) are thought to induce MH. | Hyperthermia malignant |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | This case supports the assessment that MH and diabetes are associated diseases and that cresol could possibly trigger MH. | Hyperthermia malignant |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The use of beclomethasone diproprionate inhaler complicated by the development of an eosinophilic pneumonia reaction. | Eosinophilic pneumonia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Fatal intravascular autoimmune hemolytic anemia after fludarabine treatment for chronic lymphocytic leukemia. | Autoimmune haemolytic anaemia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Physicians should be aware of the risk of severe AIHA in CLL patients with a history of AIHA or positivation of the DAT during previous fludarabine administration, or in case of secondary fixation of complement to the red cell membrane occurring during fludarabine treatment. | Autoimmune haemolytic anaemia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The occurrence of severe AIHA in CLL patients treated with fludarabine has been reported by several authors. | Autoimmune haemolytic anaemia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We report the case of a patient with chronic lymphocytic leukemia (CLL) who developed fatal intravascular autoimmune hemolytic anemia (AIHA) after fludarabine treatment. | Autoimmune haemolytic anaemia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | When the patient was treated again with fludarabine nine months later, the DAT became positive with anti-IgG and anti-C3d antiglobulins after the second course of treatment. | Coombs direct test positive |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | She had just finished a 3-week course of intravenous tobramycin for bronchiectasis and had an elevated serum tobramycin trough level 1 week before the onset of tetany. | Tetany |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Tetany in a child with AIDS receiving intravenous tobramycin. | Tetany |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | This pattern is suggestive of renal toxicity due to tobramycin. | Nephropathy toxic |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Insulin-induced lipoatrophy in type I diabetes. | Lipoatrophy |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | OBJECTIVE: To test the hypothesis that tumor necrosis factor (TNF)-alpha may mediate the loss and the dedifferentiation of subcutaneous fat tissue in the insulin-induced lipoatrophies of a diabetic patient who presented extensive lesions. | Lipoatrophy |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Methotrexate is an effective but potentially toxic treatment for psoriasis. | Exposure to toxic agent |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Painful erosion of psoriatic plaques is a less common sign of methotrexate toxicity that may precede evidence of bone marrow suppression. | Myelosuppression |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Well-known signs of methotrexate toxicity include bone marrow suppression and oral and gastrointestinal ulceration. | Myelosuppression |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | After treatment with cimetidine, there was a rapid deterioration with decreased oxygen saturation and arterial PO2 values. | Hypoxia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Caution with use of cimetidine in tolazoline induced upper gastrointestinal bleeding. | Upper gastrointestinal haemorrhage |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | However, given the clinically significant result to the interaction between tolazoline and cimetidine we report, the use of cimetidine in tolazoline induced upper gastrointestinal hemorrhage should deserve more attention. | Upper gastrointestinal haemorrhage |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Hypoxemia improved during continuous tolazoline infusion, but gastrointestinal bleeding occurred. | Gastrointestinal haemorrhage |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Zolpidem (Ambien), a relatively new nonbenzodiazepine sedative-hypnotic, was involved in the death of a 39-year-old obese male who was being treated for depression and insomnia. | Death |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Zolpidem tissue concentrations in a multiple drug related death involving Ambien. | Death |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Infants are particularly susceptible to chronic nitrate-induced methemoglobinemia because of their low stomach acid production, large numbers of nitrite-reducing bacteria, and the relatively easy oxidation of fetal hemoglobin. | Methaemoglobinaemia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | After induction of general anesthesia and administration of a standard dose of intravenous esmolol hydrochloride, her cardiac rhythm progressed to asystole. | Cardiac arrest |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Cardiac arrest after esmolol administration: a review of acute beta-blocker toxicity. | Cardiac arrest |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Atenolol induced memory impairment: a case report. | Memory impairment |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | His impaired memory was found to be due to the atenolol he was on and he made a complete recovery on withdrawing the beta-blocker. | Memory impairment |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | A potential role for renal and hepatic impairment in the observed protracted course of amiodarone-induced thyrotoxicosis is suggested. | Hyperthyroidism |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Failure of plasmapheresis, corticosteroids and thionamides to ameliorate a case of protracted amiodarone-induced thyroiditis. | Thyroiditis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We report a case of amiodarone-induced thyrotoxicosis of protracted duration, unresponsive to conventional thionamide therapy, with therapy limited by severe adverse drug reactions. | Hyperthyroidism |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Psychotic disorder associated with isoniazid. | Psychotic disorder |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We evaluated a patient who developed a psychotic disorder after 4 months of isoniazid prophylaxis for a positive tuberculosis tine test. | Psychotic disorder |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | A case report is presented concerning the administration of ketanserin in the treatment of pulmonary vasoconstriction and right ventricular failure following the infusion of protamine in a patient undergoing coronary artery bypass surgery and mitral valve replacement. | Vasoconstriction |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Ketanserin in the treatment of protamine-induced pulmonary hypertension. | Pulmonary hypertension |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The reversal of heparin by protamine may cause severe hemodynamic deterioration, characterized by systemic hypotension, pulmonary hypertension, and bronchoconstriction. | Bronchospasm |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | A drug addict with staphylococcal endocarditis treated with methicillin, who developed massive proteinuria and acute nephritic syndrome is described. | Nephritic syndrome |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Focal glomerulonephritis and interstitial nephritis in methicillin-treated, heroin-related infective endocarditis. | Glomerulonephritis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | METHODS/RESULTS: This paper presents a new case of rifabutin uveitis and a review of the various published reports to date. | Uveitis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | over the past 3 years there have been several reports of uveitis associated with rifabutin therapy. | Uveitis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Uveitis associated with rifabutin therapy: a clinical alert. | Uveitis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | CASE DESCRIPTION: A 59-year-old man with known neurocysticercosis developed a large cerebral infarction during praziquantel therapy. | Cerebral infarction |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Large cerebral infarction during praziquantel therapy in neurocysticercosis. | Cerebral infarction |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU. | Diarrhoea |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy. | Adverse reaction |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy. | Adverse reaction |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma. | Coma |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | A 49-year-old man with Crohn's disease treated with prednisone and mesalamine (5-ASA) developed worsening respiratory distress and fever. | Pyrexia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Mesalamine-induced hypersensitivity pneumonitis. | Hypersensitivity pneumonitis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Mesalamine may cause hypersensitivity pneumonitis in patients with Crohn's disease. | Hypersensitivity pneumonitis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Immunosuppression elicited by the extensive administration of prednisolone was suspected for the initiation of the generalized mite infestation. | Infestation |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | BACKGROUND: Colchicine has a known adverse effect on wound healing through its inhibitory effect on tubulin-dependent cell functions and through collagenase activation. | Impaired healing |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | CONCLUSION: The findings in these two patients suggest that colchicine may delay corneal wound healing. | Impaired healing |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Delay of corneal wound healing in patients treated with colchicine. | Impaired healing |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The authors report on two patients with corneal ulcers refractory to conventional treatment while the patients were undergoing oral colchicine therapy. | Ulcerative keratitis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The authors suggest that in patients with corneal ulcers refractory to conventional treatment who are receiving colchicine, cessation of colchicine therapy should be considered. | Ulcerative keratitis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Fulminant hepatic failure associated with bicalutamide. | Acute hepatic failure |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | A 17-year-old female patient who had been taking oral minocycline (50 mg twice daily) for 3 weeks for acne developed an eruption that progressed to an exfoliative dermatitis. | Rash |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to minocycline. | Dermatitis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Delayed hypersensitivity to flurbiprofen. | Type IV hypersensitivity reaction |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Eye movement disorders in bone marrow transplant patients on cyclosporin and ganciclovir. | Binocular eye movement disorder |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We postulate that cyclosporin, possibly together with ganciclovir, can produce transient brain stem or neuromuscular dysfunction with eye movement abnormality in occasional patients. | Binocular eye movement disorder |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | CONCLUSION: While thrombosis has been reported with GnRH-a therapy in men with prostate cancer, its association with treatment in this benign case may have been a consequence of the massive tumor size. | Thrombosis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The possible effects of tamoxifen upon the uterus are discussed in this article, in view of reports of tamoxifen associated with endometrial carcinoma and endometriosis. | Endometrial cancer |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Case study: adverse response to clonidine. | Adverse reaction |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Four cases of adverse experiences with clonidine are described. | Adverse reaction |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | In one instance a systemic hypoglycemic reaction resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of acetohexamide for acetazolamide. | Confusional state |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Discontinuation of the itraconazole caused resolution of the drug eruption. | Drug eruption |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Primary cutaneous coccidioidomycosis and subsequent drug eruption to itraconazole in a dog. | Drug eruption |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Its overall toxicity is considerably less compared to standard induction chemotherapy; however, it is associated with a high incidence of a potentially fatal symptom complex referred to as "retinoic acid syndrome." This report describes a patient with APL who developed the syndrome a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis. | Adverse event |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia. | Ventricular tachycardia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy. | Ventricular tachycardia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The probable proarrhythmic action of amiodarone, although rare, is reviewed along with a discussion of the novel use of intravenous magnesium sulfate therapy. | Arrhythmia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Acute asthma associated with sustained-release verapamil. | Asthma |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Although dyspnea associated with verapamil administration has been reported, this is the first report of an elderly asymptomatic asthmatic patient with hypertension who developed an acute asthma attack following sustained-release verapamil administration. | Asthma |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | CONCLUSIONS: Sustained-release verapamil is thought to be the cause of the asthma attack in this patient because she was not taking any other preparations; the symptoms started with the administration of sustained-release verapamil and were relieved after its discontinuation. | Asthma |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | OBJECTIVE: To describe a patient with asymptomatic bronchial asthma and hypertension who developed an acute asthma attack after receiving sustained-release verapamil. | Asthma |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | She continued taking verapamil for 6 months, then, on her own, stopped all medications including the sustained-release verapamil, and her asthma symptoms disappeared. | Asthma |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Cephalexin rash in infectious mononucleosis. | Drug eruption |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The ampicillin rash occurring in cases of infectious mononucleosis is well documented. | Drug eruption |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The case of a patient with infectious mononucleosis treated with cephalexin who later showed a rash is presented and the previous literature is reviewed. | Rash |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The rash seen in this patient, who was treated with cephalexin, may be similar to the rash seen with ampicillin treatment of patients with infectious mononucleosis. | Rash |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | A possible case of carbamazepine induced pancreatitis. | Pancreatitis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The authors report a case of acute pancreatitis (AP) occurring in a patient under treatment with carbamazepine (CBZ) for post-traumatic petit mal epilepsy, and review the current literature of drug-induced AP. | Pancreatitis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The evidence of high plasmatic levels of CBZ and the absence of other aetiologic factors lead the authors to conclude that the overdose of CBZ could have represented the precipitating of the episode of acute pancreatitis. | Pancreatitis acute |